Gillian Beamer - BA, VMD, PhD, DACVP

Gillian Beamer VMD, PhD, DACVP is Assistant Professor at Tufts University in the Department of Infectious Disease and Global Health (IDGH). She has over decade of experience studying host pathogen interactions of Mycobacterium tuberculosis, the pathogen that causes tuberculosis (TB). Additional expertise is a doctorate of veterinary medicine and a board certified veterinary pathologist, which brings breadth and depth to understanding disease pathogenesis. 


  • BA – University of Pennsylvania, 1996
  • VMD – University of Pennsylvania – 2000
  • DACVP – The Ohio State University - 2008
  • PhD –The Ohio State University - 2009

Board Certification

  • Board Certification in Veterinary Pathology (Anatomic)


1: Niazi MK, Dhulekar N, Schmidt D, Major S, Cooper R, Abeijon C, Gatti D, Kramnik I, Yener B, Gurcan M, Beamer G. Lung necrosis and neutrophils reflect common pathways of susceptibility to Mycobacterium tuberculosis in genetically diverse, immune competent mice. Dis Model Mech. 2015 Jul 23. pii: dmm.020867. [Epub ahead of print] PubMed PMID: 26204894.

2: Harrison DE, Astle CM, Niazi MK, Major S, Beamer GL. Genetically diverse mice are novel and valuable models of age-associated susceptibility to Mycobacterium tuberculosis. Immun Ageing. 2014 Dec 16;11(1):24. doi: 10.1186/s12979-014-0024-6. eCollection 2014. PubMed PMID: 25606048; PubMed Central PMCID: PMC4299371. 

3: Beamer G, Major S, Das B, Campos-Neto A. Bone marrow mesenchymal stem cells provide an antibiotic-protective niche for persistent viable Mycobacterium tuberculosis that survive antibiotic treatment. Am J Pathol. 2014 Dec;184(12):3170-5. doi: 10.1016/j.ajpath.2014.08.024. Epub 2014 Oct 16. PubMed PMID: 25451154; PubMed Central PMCID: PMC4261085. 

4: Niazi MK, Beamer G, Gurcan MN. Detecting and characterizing cellular responses to Mycobacterium tuberculosis from histology slides. Cytometry A. 2014 Feb;85(2):151-61. doi: 10.1002/cyto.a.22424. Epub 2013 Dec 12. PubMed PMID: 24339210. 

5: Major S, Turner J, Beamer G. Tuberculosis in CBA/J mice. Vet Pathol. 2013 Nov;50(6):1016-21. doi: 10.1177/0300985813482952. Epub 2013 Mar 26. PubMed PMID: 23531875. 

6: Cyktor JC, Carruthers B, Beamer GL, Turner J. Clonal expansions of CD8+ T cells with IL-10 secreting capacity occur during chronic Mycobacterium tuberculosis infection. PLoS One. 2013;8(3):e58612. doi: 10.1371/journal.pone.0058612. Epub 2013 Mar 5. PubMed PMID: 23472214; PubMed Central PMCID: PMC3589362. 

7: Cyktor JC, Carruthers B, Kominsky RA, Beamer GL, Stromberg P, Turner J. IL-10  inhibits mature fibrotic granuloma formation during Mycobacterium tuberculosis infection. J Immunol. 2013 Mar 15;190(6):2778-90. doi: 10.4049/jimmunol.1202722.  Epub 2013 Feb 8. PubMed PMID: 23396944; PubMed Central PMCID: PMC3594073. 

8: Beamer GL, Cyktor J, Flaherty DK, Stromberg PC, Carruthers B, Turner J. CBA/J  mice generate protective immunity to soluble Ag85 but fail to respond efficiently to Ag85 during natural Mycobacterium tuberculosis infection. Eur J Immunol. 2012 Apr;42(4):870-9. doi: 10.1002/eji.201142054. PubMed PMID: 22531914; PubMed Central PMCID: PMC3641789. 

9: Beamer GL, Cyktor J, Carruthers B, Turner J. H-2 alleles contribute to Antigen 85-specific interferon-gamma responses during Mycobacterium tuberculosis infection. Cell Immunol. 2011;271(1):53-61. doi: 10.1016/j.cellimm.2011.06.002. Epub 2011 Jun 12. PubMed PMID: 21714962; PubMed Central PMCID: PMC3168069. 

10: Vesosky B, Rottinghaus EK, Stromberg P, Turner J, Beamer G. CCL5 participates in early protection against Mycobacterium tuberculosis. J Leukoc Biol. 2010 Jun;87(6):1153-65. doi: 10.1189/jlb.1109742. Epub 2010 Apr 6. PubMed PMID: 20371596; PubMed Central PMCID: PMC2872537. 

11: Beamer GL, Flaherty DK, Assogba BD, Stromberg P, Gonzalez-Juarrero M, de Waal Malefyt R, Vesosky B, Turner J. Interleukin-10 promotes Mycobacterium tuberculosis disease progression in CBA/J mice. J Immunol. 2008 Oct 15;181(8):5545-50. PubMed PMID: 18832712; PubMed Central PMCID: PMC2728584. 

12: Beamer GL, Flaherty DK, Vesosky B, Turner J. Peripheral blood gamma interferon release assays predict lung responses and Mycobacterium tuberculosis disease outcome in mice. Clin Vaccine Immunol. 2008 Mar;15(3):474-83. doi: 10.1128/CVI.00408-07. Epub 2008 Jan 9. PubMed PMID: 18184822; PubMed Central PMCID: PMC2268254. 

13: Vesosky B, Flaherty DK, Rottinghaus EK, Beamer GL, Turner J. Age dependent increase in early resistance of mice to Mycobacterium tuberculosis is associated  with an increase in CD8 T cells that are capable of antigen independent IFN-gamma production. Exp Gerontol. 2006 Nov;41(11):1185-94. Epub 2006 Oct 6. PubMed PMID: 17029663. 

14: Flaherty DK, Vesosky B, Beamer GL, Stromberg P, Turner J. Exposure to Mycobacterium avium can modulate established immunity against Mycobacterium tuberculosis infection generated by Mycobacterium bovis BCG vaccination. J Leukoc Biol. 2006 Dec;80(6):1262-71. Epub 2006 Sep 12. PubMed PMID: 16968819. 

15: Beamer GL, Turner J. Murine models of susceptibility to tuberculosis. Arch Immunol Ther Exp (Warsz). 2005 Nov-Dec;53(6):469-83. Review. PubMed PMID: 16407780. 

Experimental Pathology

1: Jose RR, Raja WK, Ibrahim AM, Koolen PG, Kim K, Abdurrob A, Kluge JA, Lin SJ, Beamer G, Kaplan DL. Rapid prototyped sutureless anastomosis device from self-curing silk bio-ink. J Biomed Mater Res B Appl Biomater. 2015 Oct;103(7):1333-43. doi: 10.1002/jbm.b.33312. Epub 2014 Nov 11. PubMed PMID: 25385518; PubMed Central PMCID: PMC4427544. 

2: Sponseller JK, Steele JA, Schmidt DJ, Kim HB, Beamer G, Sun X, Tzipori S. Hyperimmune bovine colostrum as a novel therapy to combat Clostridium difficile infection. J Infect Dis. 2015 Apr 15;211(8):1334-41. doi: 10.1093/infdis/jiu605. Epub 2014 Nov 7. PubMed PMID: 25381448; PubMed Central PMCID: PMC4447838. 

3: Sheoran AS, Dmitriev IP, Kashentseva EA, Cohen O, Mukherjee J, Debatis M, Shearer J, Tremblay JM, Beamer G, Curiel DT, Shoemaker CB, Tzipori S. Adenovirus  vector expressing Stx1/Stx2-neutralizing agent protects piglets infected with Escherichia coli O157:H7 against fatal systemic intoxication. Infect Immun. 2015  Jan;83(1):286-91. doi: 10.1128/IAI.02360-14. Epub 2014 Nov 3. PubMed PMID: 25368111; PubMed Central PMCID: PMC4288880. 

4: Cohen OR, Steele JA, Zhang Q, Schmidt DJ, Wang Y, Hamel PE, Beamer G, Xu B, Tzipori S. Systemically administered IgG anti-toxin antibodies protect the colonic mucosa during infection with Clostridium difficile in the piglet model. PLoS One. 2014 Oct 27;9(10):e111075. doi: 10.1371/journal.pone.0111075. eCollection 2014. PubMed PMID: 25347821; PubMed Central PMCID: PMC4210241. 

5: Kim HB, Zhang Q, Sun X, Beamer G, Wang Y, Tzipori S. Beneficial effect of oral tigecycline treatment on Clostridium difficile infection in gnotobiotic piglets. Antimicrob Agents Chemother. 2014 Dec;58(12):7560-4. doi: 10.1128/AAC.03447-14. Epub 2014 Sep 29. PubMed PMID: 25267665; PubMed Central PMCID: PMC4249528. 

6: Mukherjee J, Dmitriev I, Debatis M, Tremblay JM, Beamer G, Kashentseva EA, Curiel DT, Shoemaker CB. Prolonged prophylactic protection from botulism with a single adenovirus treatment promoting serum expression of a VHH-based antitoxin protein. PLoS One. 2014 Aug 29;9(8):e106422. doi: 10.1371/journal.pone.0106422. eCollection 2014. PubMed PMID: 25170904; PubMed Central PMCID: PMC4149568. 

7: Tremblay JM, Mukherjee J, Leysath CE, Debatis M, Ofori K, Baldwin K, Boucher C, Peters R, Beamer G, Sheoran A, Bedenice D, Tzipori S, Shoemaker CB. A single VHH-based toxin-neutralizing agent and an effector antibody protect mice against challenge with Shiga toxins 1 and 2. Infect Immun. 2013 Dec;81(12):4592-603. doi: 10.1128/IAI.01033-13. Epub 2013 Sep 30. PubMed PMID: 24082082; PubMed Central PMCID: PMC3837998.  

8: Steele J, Zhang Q, Beamer G, Butler M, Bowlin T, Tzipori S. MBX-500 is effective for treatment of Clostridium difficile infection in gnotobiotic piglets. Antimicrob Agents Chemother. 2013 Aug;57(8):4039-41. doi: 10.1128/AAC.00304-13. Epub 2013 May 20. PubMed PMID: 23689716; PubMed Central PMCID: PMC3719748.  

Diagnostic Pathology

1: Gornik KR, Pirie CG, Beamer GL. Unilateral choristoma of the nictitating membrane in a horse. J Am Vet Med Assoc. 2015 Jan 15;246(2):231-5. doi: 10.2460/javma.246.2.231. PubMed PMID: 25554940. 

2: Dubin AJ, Pizzirani S, Beamer GL. Corneal sequestrum in a dog with chronic unilateral keratoconjunctivitis sicca. J Am Vet Med Assoc. 2013 Dec 15;243(12):1751-5. doi: 10.2460/javma.243.12.1751. PubMed PMID: 24299547. 

3: Martin-Vaquero P, da Costa RC, Simmons JK, Beamer GL, Jäderlund KH, Oglesbee MJ. A novel spongiform leukoencephalomyelopathy in Border Terrier puppies. J Vet Intern Med. 2012 Mar-Apr;26(2):402-6. doi: 10.1111/j.1939-1676.2011.00873.x. Epub 2012 Jan 23. PubMed PMID: 22269031. 

4: Hosoya K, Kisseberth WC, Alvarez FJ, Lara-Garcia A, Beamer G, Stromberg PC, Couto CG. Adjuvant CCNU (lomustine) and prednisone chemotherapy for dogs with incompletely excised grade 2 mast cell tumors. J Am Anim Hosp Assoc. 2009 Jan-Feb;45(1):14-8. PubMed PMID: 19122059. 

5: Gerspach C, Hull BL, Rings DM, Chew DJ, Beamer GL, Hubbell JA, Lakritz J. Hematuria and transitional cell papilloma of the renal pelvis treated via unilateral nephrectomy in an alpaca. J Am Vet Med Assoc. 2008 Apr 15;232(8):1206-9. doi: 10.2460/javma.232.8.1206. PubMed PMID: 18412535. 

General Research Interests

  • Tuberculosis
  • Experimental pathology

Selected Research Projects

Our main research projects focus on Mycobacterium tuberculosis, the pathogen that causes tuberculosis (TB) in susceptible individuals. We have three areas of research.

  • Identification of granuloma features and biomarkers of TB susceptibility in genetically heterogeneous populations. To do this we collaborate with computer scientists to apply cutting edge data mining, machine learning, and image-analysis algorithms to complex data sets. The process develops and applies novel computational tools for genetic mapping of susceptibility traits using Diversity Outbred mice. The goal is to generate testable models that can predict the outcome of infection before disease occurs.
  • Identifying mechanisms by which CD271+ bone marrow mesenchymal stem cells protect M. tuberculosis bacilli from the host immune response and from antibiotics. The goal is to identify the molecules that mediate protection and develop therapies targeted against those molecules.
  • Develop and test diagnostic platforms using novel immunosensing molecules that can detect proteins or other from M. tuberculosis. This would lead to the development and production of an inexpensive point-of-care test for TB.

Additional research projects include experimental pathology in other models of Infectious disease and inflammation.


  • Pathology
  • Infectious disease
  • Problem based learning
  • Mentoring students in research

Major Specialized Equipment

  • New England Regional Biosafety Laboratory
Additional Affiliations
  • Tufts Clinical and Translational Science Institute
  • Tufts institute for Innovation

Current laboratory personnel
  • Claudia Abeijon-Gherbesi, PhD

Former members and students:

  • Samuel Major
  • Matthew Huang
  • Rachel Cooper
  • Nicolas Cruz